← All trials
NCT04851015
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Dec 31, 2024
- Completion date
- Mar 31, 2025
- First posted
- Apr 20, 2021
- Last posted
- Apr 22, 2021
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- McGill UniversityLead sponsor
- McGill UniversityOverall official - principal investigator
- McGill UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.